BSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,875.00
- Market cap
- ₹35,571 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.2×Sector 46.1×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Emcure Pharmaceuticals Legal & Regulatory
Emcure Pharmaceuticals received Income-tax Department orders imposing aggregate penalties of Rs. 57.74 Crore for assessment years 2015-16 to 2021-22. The company is evaluating legal remedies.
- Value
- ₹57.74 Cr
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Other board meeting date announcements
All →Tapi Fruit Processing Board Meeting Date
Tapi Fruit Processing will hold a board meeting on November 3, 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes from October 1 to November 5, 2026.
Parag Milk Foods Board Meeting Date
Parag Milk Foods has notified BSE of a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Trading window closure runs from 1 October to 5 November 2026.
Vedant Fashions Board Meeting Date
Vedant Fashions will hold a board meeting on 5 November 2026 to consider unaudited results for the quarter and half-year ended September 2026. The meeting is a prior intimation, so no results are approved yet.
Dangee Dums Board Meeting Date
Dangee Dums will hold a board meeting on 2 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. Trading window closure runs until 4 November 2026.
Relic Technologies Board Meeting Date
Relic Technologies intimated a board meeting on 2 Nov 2026 to consider unaudited standalone and consolidated Q2 results for the period ended 30 Sep 2026. The trading window closes from 1 Oct 2026 until 48 hours after the results are disseminated.
EPL Board Meeting Date
EPL will hold a board meeting on November 4, 2026 to consider September quarter results. Trading window re-opens 48 hours after results are declared.